
USFDANov 18, 2026, 04:31 PM
InspireMD Completes First Commercial TCAR Procedures with CGuard Prime
AI Summary
InspireMD, Inc. has successfully completed the first U.S. commercial transcarotid artery revascularization (TCAR) procedures using its CGuard® Prime TransCarotid Stent System. This milestone follows the FDA's pre-market approval on November 9, 2026, and marks the expansion of the CGuard Prime platform's commercial application to TCAR procedures. The company aims to offer a comprehensive TCAR solution with its proprietary MicroNet™ mesh-covered stent technology and its developing SwitchGuard™ neuroprotection system.
Key Highlights
- InspireMD completes first U.S. commercial TCAR procedures with CGuard® Prime TransCarotid Stent System.
- FDA granted pre-market approval (PMA) for the CGuard® Prime device on November 9, 2026.
- The CGuard® Prime system utilizes InspireMD's proprietary MicroNet™ mesh-covered stent technology.
- The CGUARDIANS II pivotal trial reported 100% acute device success with no adverse events at 30 days.
- InspireMD is developing SwitchGuard™, a proprietary transcarotid neuroprotection system, currently in the CGUARDIANS III study.
Price Impact
More from NSPR